Evidence map›Paper›PMID 19213945›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2009

Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation.

Robin P Choudhury, Edward A Fisher

Abstract readReview
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Article
  2. Review
  3. MyeloidThe Journal of biological chemistry · 2019
    Article
  4. Article
  5. Molecular Imaging in Drug Discovery and Development.Circulation. Cardiovascular imaging · 2018
    Review
  6. Peptide-based fibrin-targeting probes for thrombus imaging.Dalton transactions (Cambridge, England : 2003) · 2017
    Review
  7. Article
  8. Positron Emission Tomography and Magnetic Resonance Imaging of Cellular Inflammation in Patients with Abdominal Aortic Aneurysms.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2016
    Article
  9. Review
  10. Article
  11. PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014
    Article
  12. Multimodality PET/MRI agents targeted to activated macrophages.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014
    Article
  13. Article
  14. Article
  15. Article
  16. Delivery of Polymeric Nanoparticles to Target Vascular Diseases.Journal of biomolecular research & therapeutics · 2014
    Article
  17. Molecular imaging in cardiovascular disease: Which methods, which diseases?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2013
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robin P ChoudhuryDepartment of Cardiovascular Medicine, University of Oxford, UK. robin.choudhury@cardiov.ox.ac.uk
Edward A Fisher

Funding

Nanoparticles for Molecular MRI of AtherosclerosisR01HL078667 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FAYAD, ZAHI A. · 2004 to 2008
$2.5M
British Heart Foundation PG/02/079/14128British Heart Foundation PG/08/016/24514NHLBI NIH HHS R01 HL078667NHLBI NIH HHS R01HL078667Wellcome Trust 076994
6 · The paper itself

Abstract

Appreciation of the molecular and cellular processes of atherosclerosis, thrombosis, and vascular inflammation has identified new targets for imaging. The common goals of molecular imaging approaches are to accelerate and refine diagnosis, provide insights that reveal disease diversity, guide specific therapies, and monitor the effects of those therapies. Here we undertake a comparative analysis of imaging modalities that have been used in this disease area. We consider the elements of contrast agents, emphasizing how an understanding of the biology of atherosclerosis and its complications can inform optimal design. We address the potential and limitations of current contrast approaches in respect of translation to clinically usable agents and speculate on future applications.

Indexed as

AtherosclerosisBiosensing TechniquesContrast MediaDiagnostic ImagingHumansPeptide LibraryContrast MediaPeptide Library

Identifiers

PMID19213945
PMCPMC2699351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.